CCF Highlights

Dr Michael E. Lidsky described a novel investigative murine model of FGFR2 fusion–positive intrahepatic cholangiocarcinoma and how it may enhance treatment outcomes.

Dr Cecilia Monge presented the rationale and study design for a new phase 2 study investigating the CD40 agonist CDX-1140 in combination with capecitabine, oxaliplatin, and pembrolizumab in advanced biliary tract cancer.

Dr Tim F. Greten discussed emerging targets for the treatment of cholangiocarcinoma coming from translational research studies.

Dr Mark O’Hara discussed the growing potential of CAR T-cell therapy in cholangiocarcinoma.

Dr Sandra J. Casak discussed future thinking regarding clinical trials in cholangiocarcinoma, including a “seamless” oncology drug development paradigm.

A phase 3 study showed that the addition of cytotoxic chemotherapy to the PD-L1 inhibitor durvalumab was associated with promising antitumor activity as first-line treatment for patients with advanced biliary tract cancer.

In a Cholangiocarcinoma (CCA) Foundation meeting session, Dr Francesco Facchinetti from the Gustave Roussy Cancer Campus discussed novel approaches to overcome FGFR resistance in FGFR-altered CCA.

In a Cholangiocarcinoma (CCA) Foundation meeting session, Dr Zachariah H. Foda from the Johns Hopkins School of Medicine discussed the role of circulating tumor DNA in early detection and disease monitoring for CCA.

At the Cholangiocarcinoma (CCA) Foundation meeting, Dr Mark Yarchoan from the Johns Hopkins School of Medicine presented his fellowship project focused on deciphering immune micro-environments in molecularly defined CCA subsets.